<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905033</url>
  </required_header>
  <id_info>
    <org_study_id>10-056</org_study_id>
    <nct_id>NCT01905033</nct_id>
  </id_info>
  <brief_title>Molecular Diagnosis and Risk Stratification of Sepsis</brief_title>
  <acronym>MARS</acronym>
  <official_title>Molecular Diagnosis and Risk Stratification of Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Translational Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Microbiome</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immunetrics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Check-Points</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biocartis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immunexpress</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Sepsis is a major cause of in-hospital morbidity and mortality. Current tools
      available to the clinician to initiate therapy of patients with sepsis mainly comprise of
      symptom classification systems and culture techniques, which provide aspecific and slow
      information.

      Objective: The ultimate goal of this program is to assist the physician at the bedside in
      tailoring the treatment of an individual patient suffering from sepsis by generating rapid
      molecular information about the causative pathogen and the host response.

      Deliverables: Rapid tests (&quot;sample-in-result-out&quot;) that can be used by health care personnel
      at or close to the bedside and that provide rapid information (within two hours) about the
      presence or absence of sepsis, the causative pathogen and the risk of the individual patient
      for sepsis complications and death.

      Design: The program is organized into four Work Packages (WPs) along a clinical, discovery
      and technology platform. In WP1 two university hospitals will enroll 7500 patients admitted
      to the Intensive Care Unit during the first 3 years of the project; 25% - 40% of these
      patients will have or will develop sepsis. In WP2 (Pathogen Detection), blood obtained from
      these patients will be used to develop rapid, fully automated DNA-based bedside tests that
      identify microorganisms and also provide information about their resistance to antibiotics.
      In WP3 (Host Response), RNA from blood cells will be analyzed to find novel biomarkers and to
      develop rapid and easy to perform tests that provide information about the risk profile of
      the patient. In addition, plasma levels of selected protein biomarkers will be measured for
      comparison of their value with that of the identified leukocyte molecular signatures. WP4 is
      responsible for the ICT management of the project. The Clinical Platform (covered by WP1 and
      WP4) delivers patient data and biological samples to the discovery and technology platforms.
      The Discovery Platform (covered by WP2 and WP3) uses patient data and biological samples to
      develop tests for detection of the infectious agent causing sepsis and for stratification of
      patients according to their risk for sepsis complications, including death. The results
      generated within the discovery platform will be delivered to the technology platform. The
      Technology Platform (part of WP2 and WP3) has the specific aim to develop rapid assays that
      run on a fully automated (micro)fluidics platform that is so easy to operate that it can be
      used in decentralized settings such as (close to) the ICU. The developed assays will make use
      of the knowledge generated in the discovery platform.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Molecular information about causative pathogens and the host response in patients with sepsis</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stratification of septic patients by severity and type of immune response to infection</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">7500</enrollment>
  <condition>Sepsis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma, RNA, DNA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In 3-4 years all patients&gt; 18 years in the Intensive Care Units of the AMC Amsterdam and
        UMC Utrecht will be included in the study with the exemption of elective cardiac surgery
        patients with an uncomplicated stay.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients&gt; 18 years in the Intensive Care Units of the AMC Amsterdam and UMC
             Utrecht.

        Exclusion Criteria:

          -  Elective cardiac surgery patients with an uncomplicated stay.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom van der Poll, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom van der Poll, Prof.</last_name>
    <phone>+31205665910</phone>
    <email>t.vanderpoll@amc.uva.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc J Bonten, Prof.</last_name>
      <email>mbonten@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Marc J. Bonten, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>T. van der Poll</investigator_full_name>
    <investigator_title>Prof. dr. T. van der Poll</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Peritonitis</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Transcriptomics</keyword>
  <keyword>Pathogen detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

